TCM
ITCI

Tekla Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Tekla Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$8.32M Sell
131,435
-40,936
-24% -$2.55M 0.33% 64
2023
Q1 		$9.33M Hold
172,371
– – 0.36% 59
2022
Q4 		$9.12M Hold
172,371
– – 0.34% 59
2022
Q3 		$8.02M Sell
172,371
-71,066
-29% -$3.71M 0.33% 60
2022
Q2 		$13.9M Sell
243,437
-47,499
-16% -$2.69M 0.55% 53
2022
Q1 		$17.8M Buy
290,936
+54,489
+23% +$2.83M 0.63% 42
2021
Q4 		$12.4M Sell
236,447
-87,954
-27% -$3.69M 0.4% 58
2021
Q3 		$12.1M Buy
324,401
+121,645
+60% +$4.23M 0.39% 62
2021
Q2 		$8.28M Sell
202,756
-29,720
-13% -$1.1M 0.27% 95
2021
Q1 		$7.89M Sell
232,476
-133,700
-37% -$4.64M 0.27% 94
2020
Q4 		$11.6M Buy
366,176
+271,938
+289% +$7.15M 0.41% 72
2020
Q3 		$2.42M Hold
94,238
– – 0.09% 142
2020
Q2 		$2.42M Hold
94,238
– – 0.09% 152
2020
Q1 		$1.45M Hold
94,238
– – 0.07% 153
2019
Q4 		$3.23M Buy
94,238
+66,690
+242% +$800K 0.12% 134
2019
Q3 		$206K Sell
27,548
-27,548
-50% -$264K 0.01% 181
2019
Q2 		$715K Sell
55,096
-55,097
-50% -$707K 0.03% 174
2019
Q1 		$1.34M Hold
110,193
– – 0.05% 146
2018
Q4 		$1.25M Buy
110,193
+75,343
+216% +$1.22M 0.05% 153
2018
Q3 		$756K Buy
+34,850
New +$729K 0.03% 186
2016
Q3 		– Sell
-187,800
Closed -$7.29M – 155
2016
Q2 		$7.29M Hold
187,800
– – 0.3% 73
2016
Q1 		$5.22M Hold
187,800
– – 0.22% 83
2015
Q4 		$10.1M Buy
187,800
+37,800
+25% +$1.91M 0.37% 58
2015
Q3 		$6.01M Sell
150,000
-77,164
-34% -$2.52M 0.22% 93
2015
Q2 		$7.26M Buy
227,164
+77,164
+51% +$1.96M 0.26% 72
2015
Q1 		$3.58M Buy
+150,000
New +$3.36M 0.14% 92

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tekla Capital Management's ITCI Position: Q2 2023 in Review

Tekla Capital Management reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 24% in Q2 2023, selling an estimated $2.55M and leaving 131,435 shares worth $8.32M. The position accounts for 0.33% of the portfolio, ranked #64.

Tekla Capital Management first reported a position in ITCI in Q1 2015 and has held it in 26 quarters since. The position peaked at $17.8M in Q1 2022. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Tekla Capital Management held 131,435 shares of Intra-Cellular Therapies Inc. worth $8.32M as of Q2 2023.
  • Tekla Capital Management sold 40,936 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $2.55M.
  • Intra-Cellular Therapies Inc. made up 0.33% of Tekla Capital Management's portfolio in Q2 2023, its #64 holding.
  • Tekla Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and has held it in 26 quarters since.
  • Tekla Capital Management's Intra-Cellular Therapies Inc. position peaked at $17.8M in Q1 2022.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.